ISO 21973: Standardizing Best Practices for Transporting Cell and Gene Therapies

September 30, 2020

The much-anticipated ISO 21973:2020 has arrived, supplying a set of guidelines and best practices for the transportation of cell and gene therapies. Cryoport’s experts played a role in developing these important new standards, and in a new article for Pharma’s AlmanacCryoport Systems CEO Mark Sawicki and VP of BioServices Rob Jones break down the implications of ISO 21973. 

“Cell and gene therapies are not only significantly more expensive than traditional therapies but may represent an irreplaceable, final opportunity to treat certain patients,” Sawicki and Jones write. "While it is impossible to truly eliminate all risks during transportation, these new standards aim to establish consistency and mitigate as much risk as possible.” 

Read the full article on Pharma’s Almanac

Questions or comments? We welcome your feedback!

Email Us

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC